Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers.
Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers.
复制标题
DOI：
10.1016/s1474-4422(10)70105-8
复制
发表时间：
2010-07
期刊：
影响因子：
48
通讯作者：
Louis, David N.
中科院分区：
文献类型：
--
作者：
Jansen, Michael;Yip, Stephen;Louis, David N.
在过去的10年里，分子标记物在成人恶性胶质瘤的评估和管理中的应用越来越多。一些分子特征用于诊断，以帮助病理学家对肿瘤进行分类，而另一些则用于估计患者的预后。然而，最关键的是那些用于预测对某些疗法的反应的标记物，从而指导临床医生进行特定的治疗，同时避免其他潜在的有害疗法。最近，大规模的全基因组调查已被用来确定新的生物标志物，已迅速发展为诊断和预后工具。鉴于这些发展，发现新的分子检测方法的步伐将加快，以促进恶性胶质瘤患者的个性化治疗。
Over the past 10 years, there has been an increasing use of molecular markers in the assessment and management of adult malignant gliomas. Some molecular signatures are used diagnostically to help pathologists classify tumours, whereas others are used to estimate prognosis for patients. Most crucial, however, are those markers that are used to predict response to certain therapies, thereby directing clinicians to a particular treatment while avoiding other potentially deleterious therapies. Recently, large-scale genome-wide surveys have been used to identify new biomarkers that have been rapidly developed as diagnostic and prognostic tools. Given these developments, the pace of discovery of new molecular assays will quicken to facilitate personalised medicine in the setting of malignant glioma.